. Author manuscript; available in PMC: 2021 Oct 1.

Published in final edited form as: J Hypertens. 2021 Apr 1;39(4):784–794. doi: 10.1097/HJH.0000000000002784

TABLE 2.

Sensitivity analysis for association of angiotensin-converting enzyme inhibitor/AT1 blockers and primary endpoint of all-cause mortality/severe disease

Analyses, no. of studies	Pooled relative risk (95% CI)

Hartung–Knapp–Sidik–Jonkman model, n = 31	0.91 (0.78–1.07)
Studies from Asia, n = 12	0.74 (0.54–1.16), I² = 51.1%
Studies from Europe, n = 13	1.05 (0.97–1.13), I² = 30.9%
Studies from North America, n = 6	0.93 (0.82–1.06), I² = 41.3%
Sample size < 1000, n = 18	0.92 (0.77–1.11), I² = 11.5%
Sample size ≥ 1000, n = 13	0.95 (0.86–1.05), I² = 73.3%
Studies reporting outcomes as odds ratio/relative risk, n = 23	0.91 (0.82–1.02), I² = 14.3%
Studies reporting outcomes as hazards ratio, n = 8	0.98 (0.87–1.1), I² = 76.8%

CI, confidence interval.